Today s Dietitian magazine, the leading news source for dietitians and nutritionists, covering topics such as diabetes management, long-term care, new products and technologies, career strategies, nutrition research updates, supplements, culinary arts, food allergies, fitness, sports medicine, and much more.
In January 2022, the U.S. Food and Drug Administration (FDA) released finalized guidance on premarket pathways for combination products. While the guidance is not.
VIVOS : Management s Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
Except for statements of historical fact, certain information described in this
Form 10-Q report contains forward-looking statements that involve substantial
risks and uncertainties. You can identify these statements by forward-looking
words such as anticipate, believe, could, estimate, expect, intend, may, should, will, would or similar words. The statements that contain
these or similar words should be read carefully because these statements discuss
the Company s future expectations, including its expectations of its future
results of operations or financial position, or state other forward-looking
information.
Vivos Inc. believes that it is important to communicate its future
expectations to its investors. However, there may be events in the future that
By Dhiraj Behl Amity Institute of Pharmacy, Amity University, India, Janine Jamieson, International Pharmaceutical Quality, Sweden, and Harikesh Kalonia, Amity Institute of Pharmacy, Amity University, India
Innovative, integrated delivery devices are useful for vaccines as well as treatments required for cancer, heart disease, multiple sclerosis and many more serious and chronic diseases. Drug-device combination product types include the classic prefilled syringes and pens, auto-injectors, metered-dose inhalers, dry powder inhalers, and increasingly the inclusion of connected software. However, regulation of these products is complex.
Combination products (CP) such as these are governed by two or more different sets of regulations, based on their components and primary mode of action. This can lead to challenges for regulatory authorities to agree on product review jurisdiction and also how to streamline the drug and device requirements according to philosophy, documentation, and t